Randomized Phase Iii Study Of First-Line Pembrolizumab Plus Pemetrexed/Platinum Followed By Pembrolizumab And Maintenance Olaparib Versus Pemetrexed In Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer (Nsclc): Keylynk-006.
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要